Sinco Pharmaceutical Holdings (HKSE:06833) GF Score : 53/100 (As of Jun. 05, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings GF Score?

Sinco Pharmaceutical Holdings has the GF Score of 53, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 7/10
3. Growth Rank : 2/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Sinco Pharmaceutical Holdings might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Sinco Pharmaceutical Holdings's GF Score

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinco Pharmaceutical Holdings's GF Score Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's GF Score falls into.

Sinco Pharmaceutical Holdings (HKSE:06833) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Sinco Pharmaceutical Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.

Executives

Huang Zhijian	2305 Beneficiary of a trust
Fullwealth Holdings Limited	2201 Interest of corporation controlled by you
Risun Investments Limited	2101 Beneficial owner
Wickhams Cay Trust Company Limited	2301 Trustee
Huang Xiangbin	2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines